Lourdes Mendez, MD, PhD
DownloadHi-Res Photo
Cards
Appointments
Hematology
Primary
Contact Info
About
Titles
Assistant Professor
Biography
Dr. Lourdes Mendez received her medical degree from Albert Einstein College of Medicine, as well as a PhD in Cell Biology. She completed her residency at Weill Cornell-New York Presbyterian and while a fellow in hematology/oncology at BIDMC, undertook a post-doctoral fellowship in cancer genetics. Most recently, Dr. Mendez was an Instructor of Medicine at Harvard Medical School and the Leukemia Disease Group Leader at BIDMC. She is currently a member of the Yale Leukemia Clinical and Research Team with a focus on clinical care and trials for patients with acute lymphoblastic leukemia. Dr. Mendez is dedicated to both the clinical care of patients and translational research with the goal of translating findings from the bench to the bedside to improve outcomes for patients with high-risk acute leukemia and precursor conditions (CHIP/CCUS).
Appointments
Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- Research Fellow
- Beth Israel Deaconess Medical Center (2017)
- Clinical Fellow in Hematology/Oncology
- Beth Israel Deaconess Medical Center (2014)
- Resident
- Weill Cornell-New York Presbyterian (2011)
- Intern
- Weill Cornell-New York Presbyterian (2009)
- PhD
- Albert Einstein College of Medicine, Cell Biology
- MD
- Albert Einstein College of Medicine
Research
Overview
Dr. Mendez is dedicated to both the clinical care of patients with myeloid disorders/leukemia, and translational research to identify novel therapeutics for these conditions.
Medical Subject Headings (MeSH)
Leukemia, Myeloid
Research at a Glance
Yale Co-Authors
Frequent collaborators of Lourdes Mendez's published research.
Publications Timeline
A big-picture view of Lourdes Mendez's research output by year.
Amer Zeidan, MBBS
Jennifer VanOudenhove, PhD
Natalia Neparidze, MD
Nikolai Podoltsev, MD, PhD
Rong Wang, PhD
Rory Shallis, MD
22Publications
200Citations
Publications
2023
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsChronic myeloid leukemiaTKI adherenceTKI initiationOlder patientsMyeloid leukemiaEnd Results-Medicare databaseTyrosine kinase inhibitor usePolymerase chain reaction testingQuantitative polymerase chain reaction testingOlder patient populationCare of patientsHealth care accessReal-world studyReal-world evidenceLow socioeconomic statusLow-income subsidyFirst yearInfluenza vaccinationInhibitor useWorse survivalTKI treatmentMultivariable analysisPatient populationOptimal monitoringCare accessClonal Hematopoiesis: Origins and determinants of evolution.
Mendez LM, Patnaik MM. Clonal Hematopoiesis: Origins and determinants of evolution. Leuk Res 2023, 129: 107076. PMID: 37075557, DOI: 10.1016/j.leukres.2023.107076.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSpectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms
Xie Z, Chen E, Mendez L, Komrokji R, Zeidan A. Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms. The Cancer Journal 2023, 29: 130-137. PMID: 37195768, DOI: 10.1097/ppo.0000000000000656.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAltmetricMeSH Keywords and ConceptsConceptsClonal hematopoiesisHigh-risk patientsRisk of progressionSuch patientsUndetermined significanceAge-related diseasesHematologic malignanciesClonal cytopeniaMyeloid neoplasmsHigh riskUnmet needMyeloid malignanciesNatural historyCH managementPatientsMalignancySignificant knowledge gapsRiskHematopoiesisCytopeniasNeoplasmsSyndromeIpilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Garcia JS, Flamand Y, Penter L, Keng M, Tomlinson BK, Mendez LM, Koller P, Cullen N, Arihara Y, Pfaff K, Wolff JO, Brunner AM, Galinsky I, Bashey A, Antin JH, Cutler C, Ho V, Jonas BA, Luskin MR, Wadleigh M, Winer ES, Savell A, Leonard R, Robertson T, Davids MS, Streicher H, Rodig SJ, Ritz J, Wu CJ, DeAngelo DJ, Neuberg D, Stone RM, Soiffer RJ. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood 2023, 141: 1884-1888. PMID: 36332187, DOI: 10.1182/blood.2022017686.Peer-Reviewed Original Research
2022
Is it the time to integrate novel sequencing technologies into clinical practice?
VanOudenhove J, Halene S, Mendez L. Is it the time to integrate novel sequencing technologies into clinical practice? Current Opinion In Hematology 2022, 30: 70-77. PMID: 36602939, DOI: 10.1097/moh.0000000000000754.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAltmetricMeSH Keywords and ConceptsConceptsNovel sequencing technologiesSequencing technologiesUnprecedented biological insightsNext-generation sequencing techniquesDNA sequencing technologiesHigh-throughput NGSRare cell populationsBiological insightsMultiomics approachSequencing techniquesGenotype-phenotype correlationClonal diversityCellular resolutionMechanistic insightsCell populationsPhenotype correlationMyeloid diseasesClonesClonal hierarchyClonal haematopoiesisResidual clonesInsightsSeqDiversityImproved capture
2021
Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms.
Sharda AV, Bogue T, Barr A, Mendez LM, Flaumenhaft R, Zwicker JI. Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms. Clin Cancer Res 2021, 27: 5708-5717. PMID: 34400417, DOI: 10.1158/1078-0432.CCR-21-1140.Peer-Reviewed Original Research
2020
VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2.
Sharda AV, Barr AM, Harrison JA, Wilkie AR, Fang C, Mendez LM, Ghiran IC, Italiano JE, Flaumenhaft R. VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2. Blood 2020, 136: 2824-2837. PMID: 32614949, DOI: 10.1182/blood.2020005300.Peer-Reviewed Original Research
2019
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial
Brunner A, Blonquist T, DeAngelo D, McMasters M, Fell G, Hermance N, Winer E, Lindsley R, Hobbs G, Amrein P, Hock H, Steensma D, Garcia J, Luskin M, Stone R, Ballen K, Rosenblatt J, Avigan D, Nahas M, Mendez L, McAfee S, Moran J, Bergeron M, Foster J, Bertoli C, Manning A, McGregor K, Fishman K, Kuo F, Baltay M, Macrae M, Burke M, Behnan T, Wey M, Som T, Ramos A, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg D, Chen Y, Graubert T, Fathi A. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. The Lancet Haematology 2019, 7: e122-e133. PMID: 31837959, DOI: 10.1016/s2352-3026(19)30203-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAcute myeloid leukemiaHigh-risk acute myeloid leukemiaTherapy-related acute myeloid leukemiaSecondary acute myeloid leukemiaPhase 2 trialPlatelet count recoveryInduction chemotherapyComplete remissionMyeloid leukemiaUntreated patientsEligible patientsCount recoveryDana-Farber/Harvard Cancer CenterEastern Cooperative Oncology Group performance statusUntreated acute myeloid leukemiaActivity of alisertibAdverse-risk karyotypeCommon grade 3Previous myelodysplastic syndromeTreatment-related deathsProportion of patientsPromising therapeutic targetComposite remissionFebrile neutropeniaOral alisertibThe Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy.
Mendez LM, Posey RR, Pandolfi PP. The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy. Front Oncol 2019, 9: 1162. PMID: 31781488, DOI: 10.3389/fonc.2019.01162.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsGermline NPM1 mutations lead to altered rRNA 2'-O-methylation and cause dyskeratosis congenita.
Nachmani D, Bothmer AH, Grisendi S, Mele A, Bothmer D, Lee JD, Monteleone E, Cheng K, Zhang Y, Bester AC, Guzzetti A, Mitchell CA, Mendez LM, Pozdnyakova O, Sportoletti P, Martelli MP, Vulliamy TJ, Safra M, Schwartz S, Luzzatto L, Bluteau O, Soulier J, Darnell RB, Falini B, Dokal I, Ito K, Clohessy JG, Pandolfi PP. Germline NPM1 mutations lead to altered rRNA 2'-O-methylation and cause dyskeratosis congenita. Nat Genet 2019, 51: 1518-1529. PMID: 31570891, DOI: 10.1038/s41588-019-0502-z.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
HIC ID2000035900RoleSub InvestigatorPrimary Completion Date08/31/2026Recruiting ParticipantsA Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
HIC ID2000036207RoleSub InvestigatorPrimary Completion Date01/01/2026Recruiting ParticipantsPhase I/II Open-Label Study to Assess Safety, Tolerability and Preliminary Efficacy of the CLEVER-1 Antibody Bexmarilimab in Combination With Azacitidine or Azacitidine/Venetoclax in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia
HIC ID2000034403RoleSub InvestigatorPrimary Completion Date12/31/2024Recruiting ParticipantsA Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial
HIC ID2000035577RoleSub InvestigatorPrimary Completion Date06/25/2027Recruiting ParticipantsA Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults With Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
HIC ID2000034665RolePrincipal InvestigatorPrimary Completion Date05/31/2028Recruiting Participants
Academic Achievements and Community Involvement
activity Member
Professional OrganizationsAmerican Society of HematologyDetails2007 - Present
Clinical Care
Overview
Clinical Specialties
Hematology; Hematologic Oncology
Fact Sheets
Cytogenic Studies for Leukemia Diagnosis
Learn More on Yale MedicineAcute Myeloid Leukemia (AML)
Learn More on Yale MedicineDiagnosing Leukemia
Learn More on Yale MedicineLeukemia in Children
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- March 25, 2024
Yale’s Post ASH Review
- September 11, 2023
Dr. Lourdes Mendez on Yale Cancer Answers
- October 24, 2022
Yale Hematology Welcomes Two Hematologists
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Oct 20245Saturday
Everyone Rory Shallis, MD - Nikolai Podoltsev, MD, PhD - Lourdes Mendez, MD, PhD - Joerg Bewersdorf, PhD - Lisa Barbarotta, MSN, APRN-BC, AOCNS